{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007752","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.823533+00:00","generated_at":"2026-05-21T12:04:46.041453+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Armata Q1 net loss $6.5M, cash $11.7M; AP-SA02 Phase 1b/2a topline due H1 2025","bullets":["Net loss of $6.5M ($0.18 basic EPS) vs $25.0M loss in Q1 2024; includes $5.2M non-cash gain on convertible loan.","Cash and equivalents $11.7M at March 31, 2025, up from $9.3M at Dec 31, 2024; 36.2M shares outstanding.","Topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 for S. aureus bacteremia expected in first half 2025.","Received additional $4.65M non-dilutive DoD/MTEC funding to support AP-SA02 Phase 2 close-out and FDA end-of-Phase 2 meeting.","Entered $10.0M secured credit agreement with Innoviva; existing Innoviva credit agreements extended to March 12, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007752","json":"https://secwatch.observer/filing/0001558370-25-007752.json","markdown":"https://secwatch.observer/filing/0001558370-25-007752.md","text":"https://secwatch.observer/filing/0001558370-25-007752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/0001558370-25-007752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/armp-20250514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:04:46.041453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}